Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

Completed · Phase 2 · Has a placebo group

Conditions studied: Mixed Dyslipidemia

In brief

Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluated for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator in accordance with local standards of care. After week 48, participants will be eligible and invited to consent and continue in an open-label extension study. All placebo participants who opt to continue will switch to active drug (ARO-APOC3) during the extension study.

Key facts

Study ID
NCT04998201
Run by
Arrowhead Pharmaceuticals
People needed
353
Starts
2021-09-28
Expected to finish
2023-08-14
Last updated by the study team
2026-04-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.